Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution
Autor: | Young Mi Hong, Young Joo Park, Gwang Ha Kim, Mong Cho, Sang Gyu Park, Dong Uk Kim, Hyun Young Woo, Jeong Heo, Hyung Hoi Kim, Ki Tae Yoon, Geun Am Song |
---|---|
Rok vydání: | 2021 |
Předmět: |
Cyclopropanes
medicine.medical_specialty Aminoisobutyric Acids Pyrrolidines Genotype Proline Sustained Virologic Response Sofosbuvir Lactams Macrocyclic Hepatitis C virus Hepacivirus medicine.disease_cause Antiviral Agents Cohort Studies 03 medical and health sciences 0302 clinical medicine Leucine Quinoxalines Internal medicine Republic of Korea medicine Humans Retrospective Studies Sulfonamides Intention-to-treat analysis Hepatology business.industry Gastroenterology Hepatitis C Glecaprevir Hepatitis C Chronic Middle Aged medicine.disease Pibrentasvir Treatment Outcome Tolerability 030220 oncology & carcinogenesis Benzimidazoles Drug Therapy Combination Female 030211 gastroenterology & hepatology Neoplasm Recurrence Local business Kidney disease medicine.drug |
Zdroj: | Gut and Liver. 15:440-450 |
ISSN: | 2005-1212 1976-2283 |
Popis: | Background/aims Glecaprevir/pibrentasvir (G/P) is a combination of direct-acting antiviral agents that is an approved treatment for chronic infections by all six hepatitis C virus (HCV) genotypes. However, there are limited data on the effect of G/P in Korean patients in actual real-world settings. We evaluated the real-life effectiveness and safety of G/P at a single institution in Korea. Methods This retrospective, observational, cohort study used sustained virologic response at 12 weeks after treatment completion (SVR12) as the primary effectiveness endpoint. Safety and tolerability were also determined. Results We examined 267 individuals who received G/P for chronic HCV infections. There were 148 females (55.4%), and the overall median age was 63.0 years (range, 25 to 87 years). Eighty-three patients (31.1%) had HCV genotype-1 and 182 (68.2%) had HCV-2. A total of 212 patients (79.4%) were HCV treatment-naive, 200 (74.9%) received the 8-week treatment, 13 (4.9%) had received prior treatment for hepatocellular carcinoma, 37 (13.7%) had chronic kidney disease stage 3 or higher, and 10 (3.7%) were receiving dialysis. Intention to treat (ITT) analysis indicated that 256 (95.9%) achieved SVR12. A modified ITT analysis indicated that SVR12 was 97.7% (256/262). Six patients failed therapy because of posttreatment relapse. SVR12 was significantly lower in those who received prior sofosbuvir treatment (p=0.002) and those with detectable HCV RNA at week 4 (p=0.027). Seventy patients (26.2%) experienced one or more adverse events, and most of them were mild. Conclusions These real-life data indicated that G/P treatment was highly effective and well tolerated, regardless of viral genotype or patient comorbidities. |
Databáze: | OpenAIRE |
Externí odkaz: |